Related Experiment Video
Updated: May 15, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pharmacotherapy for pneumococcal infections: an update.
Susanna Esposito1, Nicola Principi
1Pediatric Clinic 1, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milano, Italy. susanna.esposito@unimi.it
Pneumococcal disease management is challenging due to antibiotic resistance, especially in children. New vaccines may help, but protein-based vaccines are needed for complete protection against Streptococcus pneumoniae.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Pneumococcal diseases pose significant medical and economic burdens.
- Children are the most vulnerable population to pneumococcal infections.
Purpose of the Study:
- To review the optimal therapeutic strategies for pneumococcal resistance.
- To analyze Streptococcus pneumoniae susceptibility and antibiotic pharmacokinetics/pharmacodynamics.
Main Methods:
- Literature review of current therapeutic approaches.
- Analysis of antibiotic efficacy against resistant Streptococcus pneumoniae strains.
- Evaluation of pharmacokinetic and pharmacodynamic properties of antibiotics.
Main Results:
- Antibiotic treatment for many pneumococcal diseases is hindered by resistant strains.
- Drug limitations for pediatric use exacerbate treatment difficulties in children.
- Emerging conjugate pneumococcal vaccines (PCV10, PCV13) show promise in reducing infection incidence and pathogen circulation.
Conclusions:
- Effective treatment of pneumococcal infections is challenged by antibiotic resistance.
- Pediatric populations face greater risks due to limited drug options.
- Future development of broad-spectrum protein-based vaccines is crucial for comprehensive prevention of all pneumococcal infections.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
08:53Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092
Published on: October 2, 2017
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia III: Complications and Assessment
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia